APVO vs. MBRX, ERNA, MNPR, GRTX, ABVC, VAXX, AEZS, OGEN, CMMB, and ATHE
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Moleculin Biotech (MBRX), Eterna Therapeutics (ERNA), Monopar Therapeutics (MNPR), Galera Therapeutics (GRTX), ABVC BioPharma (ABVC), Vaxxinity (VAXX), Aeterna Zentaris (AEZS), Oragenics (OGEN), Chemomab Therapeutics (CMMB), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical preparations" industry.
Moleculin Biotech (NASDAQ:MBRX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by insiders. Comparatively, 0.3% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aptevo Therapeutics has higher revenue and earnings than Moleculin Biotech.
Moleculin Biotech received 29 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 53.16% of users gave Moleculin Biotech an outperform vote while only 52.66% of users gave Aptevo Therapeutics an outperform vote.
In the previous week, Moleculin Biotech and Moleculin Biotech both had 3 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.25 beat Moleculin Biotech's score of 1.11 indicating that Moleculin Biotech is being referred to more favorably in the media.
Moleculin Biotech has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.13, meaning that its stock price is 413% more volatile than the S&P 500.
Aptevo Therapeutics' return on equity of -87.19% beat Moleculin Biotech's return on equity.
Moleculin Biotech currently has a consensus price target of $35.00, suggesting a potential upside of 664.19%. Given Aptevo Therapeutics' higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Aptevo Therapeutics.
Summary
Moleculin Biotech beats Aptevo Therapeutics on 9 of the 12 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
